As part of our effort toward developing an effective therapeutic agent for c-Met-dependent tumors, a pyrazolone-based class II c-Met inhibitor, N-(4-((6, 7-dimethoxyquinolin-4-yl) oxy)- 3-fluorophenyl)-1, 5-dimethyl-3-oxo-2-phenyl-2, 3-dihydro-1 H-pyrazole-4-carboxamide (1), was identified. Knowledge of the binding mode of this molecule in both c-Met and VEGFR-2 proteins led to a novel strategy for designing more selective analogues of 1. Along with ...